Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination therapy in rheumatoid arthritis
ISRCTN18445519Phase 4Completed
- Sponsor
- Turku University Hospital
- Start
- Apr 1993
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of 5-aminosalicylic acid + sulphasalazine, methotrexate, hydroxychloroquine, prednisolone, auranofin and 1 more in rheumatoid arthritis (RA) (2 arms), sponsored by Turku University Hospital. Primary endpoint: Induction of remission. Started Apr 1993; status: completed.
02
Drugs
5-aminosalicylic acid + sulphasalazinemethotrexatehydroxychloroquineprednisoloneauranofin
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ISRCTN18445519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN18445519.